Charlotte'S Web Holdings, Inc. CWBHF
We take great care to ensure that the data presented and summarized in this overview for Charlotte's Web Holdings, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in CWBHF
Top Purchases
Top Sells
About CWBHF
Charlotte's Web Holdings, Inc. engages in farming, manufacturing, marketing, and selling hemp-derived cannabidiol (CBD) wellness products. The company's products categories include hemp extract oil tinctures, such as liquid products; gummies comprising sleep, stress, immunity, and exercise recovery products; and capsules, CBD topical creams, and lotions, as well as products for pets under the Charlotte's Web, CBD Medic, CBD Clinic, and Harmony Hemp brands. Its products contain naturally occurring phytocannabinoids, including CBD, cannabichromene, cannabigerol, cannabinol, terpenes, flavonoids, and other beneficial hemp compounds. The company distributes its products through retail outlets and health care practitioners, as well as online through its website. It has a collaboration between its CW Labs science division and the University at Buffalo's Center for Integrated Global Biomedical Sciences to advance hemp cannabinoid science through a research program; and scientific collaboration with McLean Hospital. The company was formerly known as Stanley Brothers Holdings Inc. and changed its name to Charlotte's Web Holdings, Inc. in July 2018. Charlotte's Web Holdings, Inc. was founded in 2013 and is headquartered in Denver, Colorado.
Insider Transactions at CWBHF
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 30
2024
|
William J. Morachnick Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
107,813
-7.24%
|
$0
$0.14 P/Share
|
|
Sep 30
2024
|
William J. Morachnick Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
375,000
+20.11%
|
-
|
|
Sep 03
2024
|
Raymond J. Kunkel Chief Operating Officer |
BUY
Open market or private purchase
|
Direct |
125,167
+34.29%
|
$0
$0.15 P/Share
|
|
Aug 30
2024
|
Raymond J. Kunkel Chief Operating Officer |
BUY
Open market or private purchase
|
Direct |
2,479
+2.12%
|
$0
$0.14 P/Share
|
|
Aug 29
2024
|
Raymond J. Kunkel Chief Operating Officer |
BUY
Open market or private purchase
|
Direct |
8,100
+6.73%
|
$0
$0.14 P/Share
|
|
Aug 28
2024
|
Raymond J. Kunkel Chief Operating Officer |
BUY
Open market or private purchase
|
Direct |
10,000
+8.76%
|
$0
$0.14 P/Share
|
|
Aug 27
2024
|
Raymond J. Kunkel Chief Operating Officer |
BUY
Open market or private purchase
|
Direct |
2,000
+2.08%
|
$0
$0.14 P/Share
|
|
Jun 30
2024
|
William J. Morachnick Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
107,813
-8.82%
|
$0
$0.19 P/Share
|
|
Jun 30
2024
|
William J. Morachnick Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
375,000
+23.48%
|
-
|
|
Mar 31
2024
|
William J. Morachnick Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
107,813
-11.29%
|
$0
$0.2 P/Share
|
|
Mar 31
2024
|
William J. Morachnick Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
375,000
+28.19%
|
-
|
|
Feb 01
2024
|
Thomas M Lardieri Director |
BUY
Exercise of conversion of derivative security
|
Direct |
441,176
+44.37%
|
-
|
|
Feb 01
2024
|
Raymond J. Kunkel Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
11,612
-11.2%
|
$0
$0.18 P/Share
|
|
Feb 01
2024
|
Raymond J. Kunkel Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
34,122
+10.56%
|
-
|
|
Feb 01
2024
|
John D Held Director |
BUY
Exercise of conversion of derivative security
|
Direct |
500,000
+40.02%
|
-
|
|
Feb 01
2024
|
Sarah Cambridge Principal Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,697
-34.01%
|
$0
$0.18 P/Share
|
|
Feb 01
2024
|
Sarah Cambridge Principal Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,811
+50.0%
|
-
|
|
Feb 01
2024
|
Jared Stanley Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
26,323
-14.66%
|
$0
$0.18 P/Share
|
|
Feb 01
2024
|
Jared Stanley Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
77,277
+10.95%
|
-
|
|
Feb 01
2024
|
Jessica Saxton Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
167,213
-34.05%
|
$0
$0.18 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 4.15M shares |
|---|---|
| Open market or private purchase | 148K shares |
| Payment of exercise price or tax liability | 705K shares |
|---|